Communiqués Emergent BioSolutions Inc.

Actions

EBS

US29089Q1058

Produits pharmaceutiques

Temps réel estimé Cboe BZX 15:56:12 31/08/2026			Varia. 5j.	Varia. 1 janv.
6,010 ^USD	+1,69%		+14,29%	-52,10%

14:30	Emergent BioSolutions remporte une offre à commandes pour le spray nasal Narcan au Canada	MT
07/08	Transcript : Emergent BioSolutions Inc., Q2 2026 Earnings Call, Aug 05, 2026

Communiqués

13:55	Emergent BioSolutions Awarded Government of Canada Standing Offer for NARCAN® Nasal Spray	GL
13:54	Emergent BioSolutions Reinforces Commitment to Opioid Overdose Education and Preparedness on International Overdose Awareness Day	GL
05/08	Emergent Biosolutions: Q2 Earnings Snapshot	AQ
05/08	Emergent BioSolutions Commits to Cross-Sector Collaboration Against Biological Threats in an Evolving Global Security Environment	GL
05/08	Emergent BioSolutions Commits to Cross-Sector Collaboration Against Biological Threats in an Evolving Global Security Environment	AQ
05/08	Emergent BioSolutions Reports Second Quarter 2026 Financial Results	GL
22/07	Emergent BioSolutions to Report Second Quarter 2026 Financial Results on August 5, 2026	GL
29/06	Emergent BioSolutions Secures Contract Modification Valued at Approximately $52.7 Million for ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government	GL
05/06	Emergent BioSolutions Supports Victoria's Voice Foundation's National Naloxone Awareness Day to Help Save Lives from Opioid Overdose	AQ
04/06	Emergent BioSolutions Supports Victoria’s Voice Foundation’s National Naloxone Awareness Day to Help Save Lives from Opioid Overdose	AQ
28/05	Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense Strategy	GL
20/05	Emergent BioSolutions to Participate in Upcoming Investor Conferences	GL
18/05	Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live]	GL
30/04	Emergent Biosolutions: Q1 Earnings Snapshot	AQ
30/04	Emergent BioSolutions Reports First Quarter 2026 Financial Results	GL
30/04	Emergent BioSolutions Receives Approval from Singapore Health Sciences Authority for Expanded Indication of ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) to Include Mpox	GL
29/04	Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142	GL
29/04	Emergent BioSolutions Partners with Professional Baseball Player Davis Schneider to Raise Awareness of NARCAN® Nasal Spray Among Canadians and Help Save Lives	GL
29/04	Davis Schneider's brother died of an overdose. The Blue Jay says naloxone can save others	AQ
28/04	Emergent BioSolutions and Substipharm Biologics Announce Strategic Manufacturing Partnership to Support Japanese Encephalitis Vaccine in the United States	GL
28/04	Emergent BioSolutions and Substipharm Biologics Announce Strategic Manufacturing Partnership to Support Japanese Encephalitis Vaccine in the United States	AQ
16/04	Emergent BioSolutions to Report First Quarter 2026 Financial Results on April 30, 2026	GL
16/04	Emergent BioSolutions Successfully Refinances Term Loan, Amends Asset-backed Loan Facility and Increases Financial Flexibility	GL
16/04	Emergent BioSolutions Successfully Refinances Term Loan, Amends Asset-backed Loan Facility and Increases Financial Flexibility	AQ
09/04	Emergent BioSolutions Partners with British Columbia to Supply NARCAN® Nasal Spray for the Launch of the Expanded BC Take Home Naloxone Program	GL